Accueil / À propos / Gouvernance / Conseil Consultatif Scientifique

Conseil Consultatif Scientifique

Avec des représentants de partenaires universitaires et industriels, le Comité Consultatif Scientifique examine le progrès et les performances des projets du Réseau en cours lors de l'Assemblée Générale Annuelle scientifique de GlycoNet et fait part de ses commentaires au Comité de Gestion de la Recherche.

Membres du Comité

Jeffrey Gildersleeve Dr. Gildersleeve’s group uses chemical approaches and glycan microarray technology to study the roles of anti-carbohydrate immune responses in the development, progression, and treatment of cancer and HIV. Dr. Gildersleeve is a recipient of the 2006 NCI Director’s Innovation Award and the 2011 David Y. Gin New Investigator Award from the Division of Carbohydrate Chemistry of the American Chemical Society. He also serves on the Editorial Advisory Board of ACS Central Science, the Editorial Board of the Journal of Biological Chemistry, and the Editorial Board of Cell Chemical Biology.

Directeur, Glycobiologie chimique,
Institut national du cancer
Amanda Lewis Dr. Lewis’ research combines sialic acid biology and bacterial pathogenesis to explore how members of the vaginal microbiome interact with each other and the host to enable colonization and cause disease. Her research has been recognized by faculty career awards from the American Heart Foundation, the March of Dimes, the International Glycoconjugate Organization and the Burroughs Wellcome Fund.

Professeure associée,
Washington University in St Louis
James Paulson Dr. Paulson’s research program focuses on the field of glycomics, the study of sugars on a molecular level. His work, which may have implications for the treatment of cancer, influenza, and bacterial infections, has been recognized by awards including: Melville L. Wolfram Award; Karl Meyer Award; Bijvoet Medal, Bijvoet Center for Biomolecular Research, Utrecht University; Barnett Lecture, Northeastern University; and United States EPA Green Chemistry Challenge Award.

Institut de recherche Scripps
Viliam Pavliak Dr. Pavliak is expert in a vaccine development with over 27 years of experience in industrial and academic vaccine research and development, encompassing the rationale design of glycoconjugate and peptide conjugate vaccine platforms for human diseases and the development of analytical control strategies for subunit vaccines, multi-component vaccine compositions, process intermediates and process introduced residuals.

Pavliak BioConsulting LLC
Warren Wakarchuk
Dr. Wakarchuk is a Professor from the Department of Biological Sciences at the University of Alberta. The Wakarchuk lab investigates the structure and function of the enzymes which make and degrade various glycoconjugates. This work has been enabling the chemo-enzymatic synthesis of bioactive glycoconjugates both in the laboratory and for industrial projects. The Wakarchuk lab has expertise with both mammalian and bacterial carbohydrate active enzymes for glycan remodelling applications.

Directeur scientifique,
La-Xi Wang Dr. Wang’s research group works to decipher the biological functions of glycoproteins and to design an effective carbohydrate-based HIV vaccine. Wang developed an efficient chemoenzymatic method to produce structurally well-defined, homogeneous glycoproteins highly demanded for functional glycomics studies.

University of Maryland
Linda Hseih-Wilson Research in the Hsieh-Wilson group combines organic chemistry and neurobiology to understand the molecular basis of fundamental brain processes. The Hsieh-Wilson lab applies the tools of organic synthesis, biochemistry, molecular and cellular biology, biophysics and neurobiology to manipulate and understand small molecules, proteins and molecular interactions critical for neuronal communication, development, learning and memory.

California Institute of Technology
Robert Young Current research in Dr. Young’s group is focused on the design and synthesis of novel pharmacological probes and proof-of-concept molecules for the discovery of new drug targets. Active research programs include the discovery of novel modulators of the androgen receptor for treating prostate cancer, inhibitors as anticancer therapy, and molecular probes to define the mechanism of cystic fibrosis drugs.

Université Simon Fraser

© Réseau Canadien de la Glycomique (GlycoNet). Tous droits réservés.

Scroll to Top